Sirnaomics (2257 HK)

Sirnaomics is an RNA therapeutics biopharmaceutical company that discovers and develops innovative drugs for indications with unmet medical needs. The company leverages its proprietary polypeptide nanoparticle (PNP) and GalNAc RNAi platforms (GalAhead™) to build a pipeline of drug candidates, including STP705 and STP707 for oncology and fibrosis, and STP122G for anticoagulant therapies. Headquartered in Gaithersburg, MD, United States, the company was founded in 2007.